Cutaneous Manifestations and Considerations in COVID-19 Pandemic: A Systematic Review
July 2020
in “
Dermatologic therapy
”
TLDR COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.
This systematic review from August 6, 2020, analyzed 89 articles to assess cutaneous manifestations associated with COVID-19 and provide dermatological management recommendations, particularly regarding the use of immunomodulators. The review, which completed its search on May 3, 2020, found that skin problems could be primary or secondary signs of COVID-19, commonly presenting as maculopapular or morbiliform eruptions, generalized urticaria, or "COVID toes" (pernio-like acral lesions). For non-infected patients with immune-mediated dermatologic disorders, the review suggested continuing their immunosuppressive treatments without alteration. However, at-risk or suspected patients might require adjustments such as dose reduction or temporary discontinuation of their medication for at least 2 weeks. Those with an active COVID-19 infection were advised to hold biologic or non-biologic immunosuppressives until complete recovery, which is at least 4 weeks.
